Accueil   Diary - News   All news OSIVAX appoints Dr. W. Ripley Ballou (MD) as member of its Clinical Advisory Board

OSIVAX appoints Dr. W. Ripley Ballou (MD) as member of its Clinical Advisory Board

 

Rip Ballou’s appointment will strengthen OSIVAX’s ambition to develop a pipeline of disruptive vaccines against infectious diseases.

 

Lyon, France – September 22, 2021 – OSIVAX, a biopharmaceutical company focused on the development of “universal” vaccines against mutating viruses, including influenza and coronaviruses, announced today the appointment of Dr. Ripley Ballou (MD) as member of its Clinical Advisory Board.

 

“We welcome Dr. Ballou to our clinical board.” commented Alexandre Le Vert, CEOand cofounder of OSIVAX. “We look forward to his contribution as we advance our portfolio of T-cell based vaccines, including our broad-spectrum influenzacandidate OVX836 through key clinical studies. Rip is a highly regarded leader in the field of vaccine development and his insights will help us to efficiently move our clinical programs forward.”

 

 

Read the press release